Request Quote
The official blog for all things NanoTemper

Improve the odds of your candidate becoming a drug

1 min read
Dec 19, 2018

Around 90% of all biotherapeutic candidates fail during clinical development stages. If preclinical stages are included, this number rises to nearly 99%. Lack of desirable physicochemical attributes, low efficacy, and unacceptable toxicity are some of the biggest hurdles researchers face. So, what can be done to improve the chances of a candidate becoming a drug?

Knowing as much as possible, early on about candidate molecules is important to avoid failures at a more costly time point.

Predicting the behavior of these molecules in terms of stability, aggregation, viscosity, immunogenicity is vital for evaluating potential risks and making better-educated decisions. Assessing the “developability” of new biologics helps you select the optimal candidates for advancing from discovery to development.

In this on-demand webinar, Dr. Thorsten Lorenz discusses the developability assessment strategy used at Novartis in their biologics pipeline and how they apply high-throughput stability testing to pre-formulation using NanoTemper’s Prometheus system.

Learn how you can increase the success rates of your biologics.

Working with biologics?

Sign up to receive the latest eBooks, product updates, event announcements, and more

Subscribe now